Form 4: Upstream Bio Director Erez Chimovits Acquires Stock Options

Director Erez Chimovits of Upstream Bio, Inc. reports the acquisition of stock options exercisable for 17,096 shares of common stock.

Summary

• Erez Chimovits, a director of Upstream Bio, Inc., filed a Form 4 disclosing a transaction involving derivative securities.
• On October 10, 2024, Chimovits acquired stock options representing the right to buy 17,096 shares of Upstream Bio's common stock at an exercise price of $17.
• The options vest on the earlier of October 10, 2025, or the date of the next Annual Meeting of Stockholders, contingent upon continued service.
• Chimovits is obligated to transfer any securities or economic benefits from these options to OrbiMed Advisors LLC, OrbiMed Capital GP VIII LLC, OrbiMed Israel GP II, L.P., and OrbiMed Advisors Israel II Limited, which will then provide them to OrbiMed Private Investments VIII, LP and OrbiMed Israel Partners II, L.P.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to stock option grants, indicating a neutral sentiment.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Related Party Transactions

• The Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC, OrbiMed Capital GP VIII LLC, OrbiMed Israel GP II, L.P., and OrbiMed Advisors Israel II Limited, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VIII, LP and OrbiMed Israel Partners II, L.P.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, incentivizing them to increase the company's value.

Key Dates